MDPEP

MDPEP
Legal status
Legal status	DE: Anlage II (Authorized trade only, not prescriptible); UK: Class B;
Identifiers
	IUPAC name 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylheptan-1-one;
CAS Number	746541-09-3 ; 24646-39-7 (HCl);
PubChem CID	132520294;
ChemSpider	95753889;
Chemical and physical data
Formula	C18H25NO3
Molar mass	303.402 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCC(C(=O)C1=CC2=C(C=C1)OCO2)N3CCCC3;
	InChI InChI=1S/C18H25NO3/c1-2-3-4-7-15(19-10-5-6-11-19)18(20)14-8-9-16-17(12-14)22-13-21-16/h8-9,12,15H,2-7,10-11,13H2,1H3; Key:APQUWEZHVKBPTI-UHFFFAOYSA-N;

MDPEP (also known as MD-PV8 and MDPHPP) is a substituted cathinone derivative with stimulant effects which has been sold as a designer drug. It is the longer chain heptyl homologue of the well known stimulant designer drugs MDPV and MDPHP. It was first identified in Sweden in 2019 and has been relatively widely sold, being the most commonly encountered substituted cathinone derivative found in the US in 2020–2021, though it has still not reached the same levels of use internationally as MDPV and MDPHP.^[1]^[2]^[3]

References

^ European Monitoring Center for Drugs and Drug Addiction (December 2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 9789294975584.
^ Axelsson MA, Lövgren H, Kronstrand R, Green H, Bergström MA (November 2022). "Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis". Basic & Clinical Pharmacology & Toxicology. 131 (5): 420–434. doi:10.1111/bcpt.13786. PMID 36028947. S2CID 251865526.
^ Kuropka P, Zawadzki M, Szpot P (2023). "A review of synthetic cathinones emerging in recent years (2019-2022)". Forensic Toxicology. 41 (1): 25–46. doi:10.1007/s11419-022-00639-5. PMC 9476408. PMID 36124107.

[1] European Monitoring Center for Drugs and Drug Addiction (December 2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 9789294975584.

[2] Axelsson MA, Lövgren H, Kronstrand R, Green H, Bergström MA (November 2022). "Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis". Basic & Clinical Pharmacology & Toxicology. 131 (5): 420–434. doi:10.1111/bcpt.13786. PMID 36028947. S2CID 251865526.

[3] Kuropka P, Zawadzki M, Szpot P (2023). "A review of synthetic cathinones emerging in recent years (2019-2022)". Forensic Toxicology. 41 (1): 25–46. doi:10.1007/s11419-022-00639-5. PMC 9476408. PMID 36124107.

[1]

[2]

[3]

MDPEP

See also

References